Grade My Investments
HomeFree Stock Grades › ANIP

ANI Pharmaceuticals, Inc. (ANIP) Stock Grade

ANIP · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.6B
P/E Ratio
20.2
Revenue Growth (YoY)
+43.8%
Net Margin
8.9%
Return on Equity
14.5%
Dividend Yield
0.1%

About ANI Pharmaceuticals, Inc.'s fundamentals

ANI Pharmaceuticals is a specialty and generic drug manufacturer with a market capitalization of $1.6 billion, currently trading at a P/E ratio of 20.2. The company demonstrated strong top-line growth with revenue increasing 43.8% year-over-year, though profitability remains modest with a net margin of 8.9%. Return on equity stands at 14.5%, indicating moderate efficiency in deploying shareholder capital, while the company offers minimal income to shareholders with a dividend yield of just 0.1%.

Track ANIP free — no credit card required. Live grade + monthly AI report →